Guang Tan

Dalian, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

Decomposed Multi-Modality Fusion: Integrating Frames and Events for Efficient Visuomotor Policies.

Decomposed Multi-Modality Fusion: Integrating Frames and Events for Efficient Visuomotor Policies.

Journal: IEEE transactions on pattern analysis and machine intelligence

Published: May 18, 2026

Prognostic Relevance of Neddylation-Related Genes in Hepatocellular Carcinoma.

Prognostic Relevance of Neddylation-Related Genes in Hepatocellular Carcinoma.

Journal: Journal of hepatocellular carcinoma

Published: March 18, 2026

Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine/oxaliplatin as initial treatment for advanced biliary tract cancer: a multicenter, single-arm, prospective, phase II study.

Efficacy and safety of pembrolizumab, lenvatinib, and reduced-dose gemcitabine/oxaliplatin as initial treatment for advanced biliary tract cancer: a multicenter, single-arm, prospective, phase II study.

Journal: Journal for immunotherapy of cancer

Published: January 28, 2026

Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025).

Chinese expert consensus on precision testing and molecular diagnosis of pancreatic cancer (2025).

Journal: British journal of cancer

Published: January 21, 2026

Exploratory Analysis of Gut Microbiome and Metabolic Profile Changes Following Lenvatinib and Anti-PD-1 Combination Therapy in Liver Cancer.

Exploratory Analysis of Gut Microbiome and Metabolic Profile Changes Following Lenvatinib and Anti-PD-1 Combination Therapy in Liver Cancer.

Journal: Metabolites

Published: December 22, 2025

The impact of microvascular invasion in tumor recurrence and survival after liver resection for non-B non-C hepatocellular carcinoma: a multicenter, propensity score-matched analysis.

The impact of microvascular invasion in tumor recurrence and survival after liver resection for non-B non-C hepatocellular carcinoma: a multicenter, propensity score-matched analysis.

Journal: Surgical endoscopy

Published: December 04, 2025

A novel mitochondrial-associated risk score reveals a potential link between pancreatic ductal adenocarcinoma and chemotherapy resistance as well as poor response to immunotherapy.

A novel mitochondrial-associated risk score reveals a potential link between pancreatic ductal adenocarcinoma and chemotherapy resistance as well as poor response to immunotherapy.

Journal: Discover oncology

Published: November 19, 2025

Patients with hepatitis B virus-related hepatocellular carcinoma underlying cirrhosis have higher microvascular invasion and poorer prognosis after liver resection: A multicenter study.

Patients with hepatitis B virus-related hepatocellular carcinoma underlying cirrhosis have higher microvascular invasion and poorer prognosis after liver resection: A multicenter study.

Journal: Hepatobiliary & pancreatic diseases international : HBPD INT

Published: October 13, 2025

Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.

Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial.

Journal: Lancet (London, England)

Published: July 24, 2025

Correction: Letter to the editor: "Disease severity prognostication in primary sclerosing cholangitis: a validation of the Anali scores and comparison with the potential functional stricture".

Correction: Letter to the editor: "Disease severity prognostication in primary sclerosing cholangitis: a validation of the Anali scores and comparison with the potential functional stricture".

Journal: European radiology

Published: March 17, 2025

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

Chinese expert consensus on conversion and perioperative therapy of primary liver cancer (2024 edition).

Journal: Hepatobiliary surgery and nutrition

Published: February 28, 2025

Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).

Chinese expert consensus on sequential surgery following conversion therapy based on combination of immune checkpoint inhibitors and antiangiogenic targeted drugs for advanced hepatocellular carcinoma (2024 edition).

Journal: Bioscience trends

Published: December 25, 2024

Showing 1-12 of 64

Last Updated: 09/26/2026